https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/rtgpwexe/cover_janfeb25.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/dvsf1uun/cover.jpg
Contact Lens Spectrum
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/i5xfuxqu/eb_0125_janfeb-cover.jpg
Eyecare Business
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/i1udssrm/gp_cover_nov24.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/1hxbzi3g/op_0125_cover.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/53bbqpwy/screenshot-2024-12-16-at-11437-pm.png
Optometric Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-om-staging.hbrsd.com/media/cdbhnbx2/cover_janfeb25_web.jpg
Retinal Physician
Thursday, December 26, 2024
The data and safety monitoring board reviewed data from 15 phase 2 subjects and confirmed that OCU410 (AAV5-hRORA) has a favorable safety profile, with no serious adverse events reported related to the drug.
Monday, December 23, 2024
The primary endpoint of the trial is reduction in rate of change of geographic atrophy lesion size.
Monday, December 23, 2024
The NDA submission includes data from two Phase 3 pivotal trials of Epioxa, which both successfully achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Monday, December 23, 2024
Annexin-V flags inflammatory response in addition to apoptosis, suggesting role as biomarker of ocular inflammation.
Thursday, December 19, 2024
The agreed primary endpoint is a reduction in 3-step or greater worsening on the binocular diabetic retinopathy severity scale (DRSS) score, compared to placebo.
Wednesday, December 18, 2024
The clearance allows for a Phase 1/2 trial to evaluate the therapy’s safety, tolerability and initial efficacy.
Wednesday, December 18, 2024
The primary endpoint, proportion of responders with >15 letters of improvement in BCVA, showed statistically significant improvement in the high-dose AURN001 arm (p=0.020), compared to the Y-27632-only arm.
Tuesday, December 17, 2024
HORA-PDE6b has demonstrated clinically meaningful benefits in visual functions and a good safety profile in PDE6b patients at the 24-month follow-up from the ongoing Phase 1/2 trial.
Tuesday, December 17, 2024
Aflibercept injection 8 mg showed improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion.
Monday, December 16, 2024
Company CEO Steve Mahoney says the combined results of THRIVE and THRIVE-2 make him sure that their subcutaneous VRDN-003 program will deliver positive topline data in the first half of 2026, enabling a biologics license application submission in the second half of 2026.
Monday, December 16, 2024
The potential overnight reduction of the critical oxygen supply could present a retinal health risk.
By Sarah Fackler
Monday, December 16, 2024
The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the United States, India, Brazil and Mexico.
Friday, December 13, 2024
Twelve-month study data highlight the safety and efficacy of bio-reinforced cyclodialysis in POAG
Thursday, December 12, 2024
The merger brings together the late-stage presybopia-correcting drop, BRIMOCHOL PF with a pipeline of therapeutics and a syndicate of institutional investors.
Wednesday, December 11, 2024
The acquisition provides new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants.
Tuesday, December 10, 2024
Targeting specific retinal cell types could lead to treatments that slow or stop progression.
Tuesday, December 10, 2024
Researchers will explore aqueous outflow dynamics using ViaLase’s innovative laser procedure to lower IOP.
Tuesday, December 10, 2024
Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and
Translational Vision Science & Technology focus on efficacy, vision and contrast theory.
Tuesday, December 10, 2024
The data shows promising early improvements in low luminance visual acuity, a critical measure of visual function.
Tuesday, December 10, 2024
The study builds on previously announced preliminary results on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma.
Monday, December 9, 2024
The OneSight EssilorLuxottica Foundation announced that it will collaborate with the World Health Organization's SPECS 2030, a global initiative to address refractive error, prevent myopia and improve access to vision care.
Friday, December 6, 2024
The company says the AI-powered camera will be available in the United States and Europe.
Friday, December 6, 2024
The Phase 3 trial will evaluate the safety and efficacy of the company’s Duravyu intraocular insert in patients with wet AMD.
Friday, December 6, 2024
The Phase 3 trial SOL-1 will evaluate the safety and efficacy of the Axpaxli intravitreal implant as a treatment for wet AMD.
Friday, December 6, 2024
Mr. Hunter spent more than two decades in eye care, working in rare disease and specialty markets.
Friday, December 6, 2024
A recent meta-analysis of 14 trials finds that SLT offers comparable pressure control to medications, with fewer complications.
Friday, December 6, 2024
A recent study found polygenic risk scores for glaucoma are less accurate for patients of African ancestry compared to White or Asian populations.
Friday, December 6, 2024
The findings suggest that repeat SLT is a viable treatment option for most patients with open-angle glaucoma and ocular hypertension.
Friday, December 6, 2024
At the 2-year mark, researchers reported significant reductions in IOP, with average levels decreasing from 25.43 mmHg preoperatively to 11.25 mmHg, a 50% reduction.
Thursday, December 5, 2024
VivaVision's VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.
Wednesday, December 4, 2024
The strategic alliance aims to increase access to vision screening in patients with uncontrolled diabetes and reduce the risks of diabetic retinopathy using Ainnova’s artificial intelligence technology.
Wednesday, December 4, 2024
The THEA program intends to revolutionize the reconnection of nerves to the brain and develop breakthroughs in transplantation, preservation and neuroscience, said ARPA-H Director Renee Wegrzyn, PhD.
Tuesday, December 3, 2024
The Foundation and its partners, including University of Colorado Anschutz Medical Campus, have been awarded the funds to fast-track whole-eye transplantation program.
Tuesday, December 3, 2024
The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan, latanoprost ophthalmic solution 0.005%.
Tuesday, December 3, 2024
“DON inhibited the growth of all three lines in a dose-dependent fashion, providing support for an ongoing requirement for MYC in SebCA"
By Sarah Fackler
Tuesday, December 3, 2024
Pediatricians play a key role in identifying at-risk children.
By Sarah Fackler
Monday, December 2, 2024
As part of Geographic Atrophy (GA) Awareness Week, Prevent Blindness is highlighting its free educational resources including a comprehensive fact sheet, a series of social media graphics (available in English and Spanish), a dedicated web page and expert videos.
Monday, December 2, 2024
The system allows for a simple two-step process that involves filling the viscoelastic material and pressing the plunger for quick and easy operation.
Monday, December 2, 2024
The newest member of the Tixel family of products was cleared for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction.
Monday, December 2, 2024
The company says the drug is bioequivalent and therapeutically equivalent to Sandoz's Travatan Z, a treatement for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma.
Monday, November 25, 2024
Ophthalmic procedures should be added to program that eases prior-authorization burden on physicians and practices, says the Academy.
Friday, November 22, 2024
Higher mean BP and higher BP variability were associated with faster VF deterioration.
By Sarah Fackler
Thursday, November 21, 2024
Sun Pharmaceuticals presented the data on patients switched to Cequa at the 2024 ESCRS meeting in Barcelona
Thursday, November 21, 2024
The Phase 1/2 trial will compare the IOP-reducing effect of SpyGlass Pharma's bimatoprost-eluting IOL to treatment with timolol ophthalmic solution in glaucoma patients undergoing cataract surgery.
Thursday, November 21, 2024
The $4.6 billion deal expands the drug wholesaler’s presence in specialty health care and retinal care.
Wednesday, November 20, 2024
Opioid-free Melt-300 showed itself to be safe and effective for patients undergoing cataract surgery.
Tuesday, November 19, 2024
Six-month results from the ArMaDa trial for OCU410, a 1-time therapy delivered via subretinal injection, demonstrated safety and functional vision benefits for GA patients.
Tuesday, November 19, 2024
In both TEASE-1 and TEASE-3, gildeuretinol demonstrated a favorable safety and tolerability profile with no adverse events related to hyper- or hypo-vitaminosis A such as xerophthalmia, chromatopsia, dark adaptation delays or night blindness.
Tuesday, November 19, 2024
Data from the LUNA trial, as well as the OPTIC extension study, show a reduction in anti-VEGF injections along with a favorable safety profile. The company is planning a Phase 3 trial for 2025.
Monday, November 18, 2024
The FDA accepted for review the resubmitted NDA for Aldeyra Therapeutics' topical ocular reproxalap for the treatment of dry eye disease, assigning a Prescription Drug User Fee Act date of April 2, 2025. Aldeyra also announced the expansion of its exclusive option agreement with AbbVie Inc.
Monday, November 18, 2024
Eyenovia’s Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform as a potential treatment for pediatric progressive myopia did not meet its primary endpoint.
Friday, November 15, 2024
The study demonstrated that LL-BMT1, in a 32-µg dose, achieved equivalent IOP reduction to bimatoprost 0.01% drops.
Wednesday, November 13, 2024
The company's initiative includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx to provide patients with discounts on select Harrow products.
Wednesday, November 13, 2024
The PDUFA date for Neurotech Pharmaceuticals's NT-501 has been pushed to March 2025.
Wednesday, November 13, 2024
The primary endpoint will be changes in BCVA at weeks 52 and 56, with secondary measures including safety and the need for supplemental injections.
Tuesday, November 12, 2024
Millions more patients will have access to the dry eye treatment in 2025.
Tuesday, November 12, 2024
The combined company will focus on the development of TH103, a novel therapy for patients with neovascular and exudative retinal diseases.
Tuesday, November 12, 2024
LifeLink Tissue Bank announced a strategic relationship with BioTissue to enhance the use of placental tissue recovered following healthy deliveries, which BioTissue will transform into therapies for patients in need.
Tuesday, November 12, 2024
Researchers found not only substantial direct and indirect medical costs, but also significant effects on well-being and productivity.
By Sarah Fackler
Tuesday, November 12, 2024
The objectiveFIELD bilateral visual field analyzer measures pupillary responses to spatially resolved stimuli, captured by video cameras under infrared conditions.
Thursday, November 7, 2024
Findings from a retrospective study on PST-611, the company's transferrin vectorized treatment, were presented at EVER Congress 2024.
Tuesday, November 5, 2024
FELIQS plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Japan in 1Q2025
Tuesday, November 5, 2024
Prevent Blindness provides the public and professionals with free web pages, fact sheets, educational videos, toolkits, and social media graphics, to help prevent vision loss and blindness from diabetes.
Tuesday, November 5, 2024
Valeda provides an improvement in BCVA over 24 months of >5 letters or equivalent to a line on the eye chart.
Monday, November 4, 2024
Under the final rule, ASC payment rates will be updated by 2.9% in 2025, representing an average across all ASC procedures.
Friday, November 1, 2024
EyePoint Pharmaceuticals' DURAVYU 2.7 mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline.
Monday, October 28, 2024
Patients with glaucoma or ocular hypertension implanted with SpyGlass Pharma’s Drug Delivery Platform showed a mean 43.7% reduction in IOP at 18 months, compared to baseline.
Monday, October 28, 2024
The CDRH is responsible for overseeing the safety, effectiveness, and quality of medical devices and radiation-emitting products in the United States.
Monday, October 28, 2024
Survey findings show fewer than 30% of caregivers of persons at risk for retinal diseases have heard about some of the most common types of diseases that affect older adults.
Thursday, October 24, 2024
OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial, the company said.
Thursday, October 24, 2024
Patients with late stage dry AMD regained the ability to read and recognize faces after receiving the PRIMA retinal implant.
Wednesday, October 23, 2024
A recently published study found that microdose spray with Eyenovia’s Optojet reduces the harmful effect of preservatives in eyedrops.
Wednesday, October 23, 2024
The acquisition creates a clinical-stage company with a strong focus on gene therapies for rare inherited retinal diseases.
Monday, October 21, 2024
Phase 3 confirmatory trial met pre-specified primary efficacy endpoint and demonstrated excellent tolerability and a favorable safety profile through 12 months
Monday, October 21, 2024
LNZ 100 is the first and only aceclidine-based eyedrop to improve near vision in people with presbyopia, the company says.
Monday, October 21, 2024
The agreement supports the management of ocular surface disease and ocular surgery.
Friday, October 18, 2024
AAO hopes the VR Education program will help ophthalmologists expand their skills in diagnosing and treating eye diseases.
Tuesday, October 15, 2024
The company's meeting offerings include making its new Voyager Direct Selective Laser Trabeculoplasty for glaucoma therapy available for demonstration, debuting gas delivery systems, and presentation of data for pivotal drug and surgical products.
Tuesday, October 15, 2024
Adjustable suction time parameters will increase OR efficiency, the company says.
Tuesday, October 15, 2024
The infrared technology penetrates dense cataracts, hemorrhages and cloudy corneas, offering a clear visual pathway.
Tuesday, October 15, 2024
The multimodal, diagnostic imaging-only platform is designed for imaging the posterior segment of pediatric and adult patients in a supine position.
Tuesday, October 15, 2024
enVista Envy IOLs will be commercially available in the United States on a limited basis in the coming weeks and more broadly in 2025.
Friday, October 11, 2024
The iCare ST500 offers a combination of iCare rebound technology and slit lamp-based tonometry
Thursday, October 10, 2024
The clinical trial reaches another milestone, with topline results expected by year's end. And the FDA agrees to a Special Protocol Assessment.
Thursday, October 10, 2024
At the AAO annual meeting, ZEISS will showcase digital enhancements and surgical solutions across cataract, corneal refractive, retina and glaucoma workflows.
Wednesday, October 9, 2024
The collaboration between CASExGLOBAL, Clinical AI and iOR Partners introduces AI-powered Site Management Organization bringing decentralized clinical trials to ophthalmic office-based surgery centers.
Wednesday, October 9, 2024
ODYSSEY Phase 2b trial of suprachoroidal CLS-AX in wet AMD achieved all primary and secondary outcomes.
Monday, October 7, 2024
Topical ocular reproxalap is an investigational new drug candidate for the treatment of signs and symptoms of dry eye disease.
Monday, October 7, 2024
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically induced mydriasis with favorable safety profile
Thursday, October 3, 2024
After 2 years unavailable in the United States, the corticosteroid is once again on the market.
Thursday, October 3, 2024
FDA grants fast track designation for nonanterior noninfectious uveitis treatment.
Wednesday, October 2, 2024
New presbyopia-correcting IOL offers cataract patients precise vision at every distance in any lighting.
Tuesday, October 1, 2024
This latest release is tailored to support the workflows of ophthalmology and optometry, and to address the specific challenges and limitations of using ambient listening to document eye exams.
Monday, September 30, 2024
The company offers expanded training on Implantable Collamer Lenses for surgeons and their staffs.
Friday, September 27, 2024
The company says the Micor 700’s non-ultrasound approach minimizes thermal stress and tissue damage during cataract surgery.
Friday, September 27, 2024
The bottle enhances the effectiveness of the preservative-free solution, ensuring safe eyedrop administration for daily and long-term use
Friday, September 27, 2024
Clobetasol propionate ophthalmic suspension 0.05% provides a twice-a-day dosing regimen for ocular surgery patients.
Wednesday, September 25, 2024
The device integrates multiple exams such as transillumination meibography and an autofocus HD camera for sharp image quality and automatic, accurate and reproducible results.
Tuesday, September 24, 2024
The trial will compare intravitreal injection of AVD-104 to avacincaptad pegol for treatment of geographic atrophy secondary to AMD.
Tuesday, September 24, 2024
Research also highlights a potential link between allostatic load, which is a stress measurement, and racial disparities in glaucoma prevalence.
Tuesday, September 24, 2024
A new topography module has been added to Visionix USA's next-generation Optovue Solix FullRange and Solix Essential OCT and OCT angiographer systems.
Tuesday, September 24, 2024
Collaboration introduces Vista 1-Step and Vista IS products, which are intended to enhance vitrectomy procedures.
Tuesday, September 24, 2024
The agreement aims to explore the therapeutic potential of Nicox’s nitric oxide-donating PDE5 inhibitor, NCX 1728, in glaucoma treatment.
Tuesday, September 24, 2024
The collaboration focuses on developing RTC-620, a biodegradable implant that is designed to reduce IOL.
Tuesday, September 24, 2024
In early-stage choroidal melanoma patients, suprachoroidal injection of bel-sar shows 80% tumor control and 90% vision preservation.
Tuesday, September 24, 2024
Data from the SAGA study showed patients with geographic atrophy showed improved visual acuity after 2 years on the oral therapy.
Friday, September 20, 2024
MYL-1701P proves comparable to reference aflibercept at 52 weeks, according to data from the INSIGHT clinical trial.
Friday, September 20, 2024
The award, recognizing his innovative research in macular edema, was presented at the EURETINA meeting.
Thursday, September 19, 2024
The FDA designation advances a potential gene therapy treatment for X-linked retinoschisis.
Thursday, September 19, 2024
Completion of PPQ campaign for novel wet AMD treatment strengthens path to regulatory approval
Thursday, September 19, 2024
The Prevent Blindness Children’s Vision Health Map and corresponding report provides the public, professionals and policy makers with county and state-level data on children’s vision issues.
Wednesday, September 18, 2024
In a surgical first, retinal cells showed light responsiveness up to 9.0 μv at 220 days after whole eye transplant, nearing the low end of normal (10-50 μv).
Monday, September 16, 2024
The technology leverages advanced generative artificial intelligence and machine learning to automatically listen to the physician and patient during consultations.
Saturday, September 14, 2024
Topcon’s Maestro2 becomes the first robotic device available in the United States to offer OCT angiography.
Saturday, September 14, 2024
Study demonstrates the effectiveness of Iantrek’s biointerventional technology in treating open-angle glaucoma.
Wednesday, September 11, 2024
Study demonstrated a positive safety profile and met secondary and exploratory endpoints associated with subjective and objective evidence of visual function preservation at 6 months.
Wednesday, September 11, 2024
Veligrotug (VRDN-001) achieved all primary and secondary endpoints
Monday, September 9, 2024
Agency considers merging jurisdictions and extending contracts to improve efficiency.
Monday, September 9, 2024
Medicare beneficiaries may be affected by vulnerability in third-party software.
Monday, September 9, 2024
Restoret, a potential first-in-class therapy, to be tested for diabetic macular edema.
Monday, September 9, 2024
ScribeRyte AI health-care documentation solutions automates charting on a customizable platform for medical networks and hospitals.
Monday, September 9, 2024
The VEGA-3 Phase 3 clinical trial is evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia; and the LYNX-2 Phase 3 trial is evaluating Phentolamine Ophthalmic Solution 0.75% in patients with decreased visual acuity under low light conditions following keratorefractive surgery.
Wednesday, September 4, 2024
Patients using the CureSight digital eye-tracking device for amblyopia treatment achieved greater visual acuity gains in per-protocol analysis.
Wednesday, September 4, 2024
A proprietary AI engine trained on patient outcomes helped create RayOne Galaxy’s spiral, which delivers a continuous full range of vision with minimized dysphotopsia,
Tuesday, September 3, 2024
The FDA has accepted protocols and endpoints for signs and symptoms of PL9643 Phase 3 pivotal clinical trials for dry eye disease
Tuesday, September 3, 2024
The system is intended for procedures like capsulorhexis and capsular polishing.
Tuesday, September 3, 2024
The AAO warns these products have not been tested for safety or efficacy and could potentially damage the eyes.
Tuesday, August 27, 2024
Formerly Retaine MGD, the preservative-free ophthalmic emulsion for moderate to severe evaporative dry eye will launch in early 2025.
Tuesday, August 27, 2024
Data shows more than 32,600 sports eye injuries were treated in 2023, with pool and water sports as the type of sport with the most eye injuries.
Monday, August 26, 2024
Guidance would support biologic drug competition, increase patient access to biosimilars and lower health-care costs for patients, the FTC comment says.
Monday, August 26, 2024
The company's ocular gene therapy is intended for patients with an inherited early onset retinal degeneration.
Thursday, August 22, 2024
The new device features auto alignment, auto focus and auto capture functions.
Wednesday, August 21, 2024
With the merger, the company will operate under the Ocuvex name.
Tuesday, August 20, 2024
ATSN-201 aims to provide new hope for patients with X-linked retinoschisis.
Monday, August 19, 2024
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% is an alternative to the active ingredient in Pataday Twice Daily Relief.
Monday, August 19, 2024
The drug is a generic equivalent to Bausch + Lomb's Lumify.
Monday, August 19, 2024
TV and radio spots highlight the importance of seeing a retina specialist to prevent blindness
Wednesday, August 14, 2024
The drug is indicated for treatment of neovascular AMD, also known as wet AMD.
Tuesday, August 13, 2024
Program will focus on identifying and removing barriers to care facing Black and Hispanic/Latino communities in the Washington, DC region.
Tuesday, August 13, 2024
Study achieved its primary endpoint of therapeutic equivalence in visual acuity improvement for wet AMD patients, showcasing comparable safety and immunogenicity between LUBT010 and Lucentis.
Tuesday, August 13, 2024
Phase 3 SOL-R clinical trial is acceptable for use as the company’s second adequate and well-controlled study of AXPAXLI for the treatment of wet AMD.
Tuesday, August 13, 2024
Establishing a CPT code for photobiomodulation use in retina marks a positive step toward reimbursement.
Tuesday, August 13, 2024
Data revealed reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort.
Monday, August 12, 2024
LNZ100 is an aceclidine-based ophthalmic solution intended to treat presbyopia.
Monday, August 5, 2024
The EYE6 with Ivy leverages advanced multimodal generative AI and large language models to help users improve their daily living experiences and independence.
Monday, August 5, 2024
Along with educational resources, the organization is drawing attention to legislation to fund children’s vision programs.
Monday, August 5, 2024
The stand's features can be customized to allow the operator to program well cups and control room lights, reading lamp brightness and BIO brightness directly from the built-in touchscreen panel.
Monday, August 5, 2024
In-person summit will feature 18+ course hours and an extensive resource library to support practice adoption of advanced-technology IOLs
Monday, July 29, 2024
Partnership to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet dispensing technology
Friday, July 26, 2024
This designation expedites the technology’s development and review process and supports reimbursement and timely access for patients and health-care providers.
Thursday, July 25, 2024
Preliminary results in a nonhuman trial indicate a potential pathway for recovery of optic nerve function in glaucoma patients.
Thursday, July 25, 2024
Analysis of data from the GATHER trials found eyes with greater ellipsoid zone attenuation and larger EZ-GA gap showed faster GA growth over 12 months.
Thursday, July 25, 2024
A single injection of the gene therapy Ixo-vec reduced anti-VEGF injection burden by 90% to 95% in wet AMD patients.
Wednesday, July 24, 2024
Faros is optimized for fast setup, with a readiness time of under one minute, making it ideal for integrating into office-based surgery.
Wednesday, July 24, 2024
New analysis shows benefit to taking AREDS2 formula vitamins during the late stage of dry age-related macular degeneration.
Tuesday, July 23, 2024
The acquisition will help expand Bausch + Lomb’s surgical presence in the United States.
Tuesday, July 23, 2024
Two-year Phase 3 data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat DME and DR
Thursday, July 18, 2024
Heidelberg Engineering will continue to serve the market under its established brand
Tuesday, July 16, 2024
This next generation of OCT angiography reduces acquisition time by 50%.
Tuesday, July 16, 2024
Dr. Dohlman is considered by many to be the father of modern corneal science, whose transformative work modernized the field and continues to be widely utilized today.
Monday, July 15, 2024
A postmarketing surveillance study could be helpful in determining if there is a connection between semaglutide and NAION.
Monday, July 15, 2024
Preservative Freedom Coalition says having strong guidelines that support the use of preservative-free options will help build an environment that improves education on preservatives and will help break down barriers to access.
Friday, July 12, 2024
The deal, valued at up to $3 billion, expands Merck’s ophthalmology pipeline.
Friday, July 12, 2024
Crizanlizumab shows promise in stabilizing vision and potentially modifying disease progression in patients with the rare genetic disorder RVCL-S.
Thursday, July 11, 2024
Analysis of national data shows moderate to high cardiovascular health scores are associated with reduced odds of diabetic or hypertensive retinopathy.
Thursday, July 11, 2024
The vitrectomy systems had similar surgical times and complication rates, with 27-gauge allowing more sutureless surgeries.
Thursday, July 11, 2024
Phase 3 trials demonstrate faricimab’s potential to extend treatment intervals up to 16 weeks while maintaining visual gains in patients with diabetic macular edema.
Thursday, July 11, 2024
A Phase 2 trial of the drug demonstrates potential to delay or prevent progression of diabetic retinopathy.
Thursday, July 11, 2024
Results of the RESTORE trial indicate that MCO-010 optogenetic therapy significantly improves visual acuity in patients with retinitis pigmentosa.
Tuesday, July 9, 2024
This includes devices reviewed in the Division of Ophthalmic Devices in fall 2024
Tuesday, July 9, 2024
The FDA approved updates to Susvimo, which will be available to US retina specialists and patients with wet AMD in the coming weeks
Tuesday, July 9, 2024
Purchase includes direct selective laser trabeculoplasty technology set to become available in late 2024.
Tuesday, July 9, 2024
The biosimilar was approved to treat patients with wet AMD and other retinal diseases
Tuesday, July 9, 2024
The Vabysmo PFS will become available to US retina specialists and their patients in the coming months.
Tuesday, July 9, 2024
New online resource, KnowYourDryEye.com, aims to increase awareness and education
Tuesday, July 2, 2024
Prevent Blindness urges the public to celebrate independence day safely by avoiding fireworks, attending authorized displays by professionals
Tuesday, July 2, 2024
Company says the new J-code simplifies and ensures consistent coverage
Tuesday, July 2, 2024
Balance Ophthalmics’ non-pharmacological, non-surgical device intended to help manage IOP in normal tension and open-angle glaucoma patients.
Tuesday, July 2, 2024
Prospective trial shows impact of Home OCT guided wet AMD patient management
Wednesday, June 26, 2024
The ocular implant from Neurotech Pharmaceuticals is an investigational treatment for MacTel.
Wednesday, June 26, 2024
The $381 million deal expands ANI’s presence in ophthalmology.
Monday, June 24, 2024
Vitreoretinal Cataract System and Cataract System are the first solutions to be introduced from Alcon’s Unity portfolio of surgical equipment
Friday, June 21, 2024
Approval was based on positive results from the CHAMPION-NMOSD Phase 3 trial.
Thursday, June 20, 2024
Full production of Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL may be restarting later this year after 5 years on the FDA Drug Shortage list.
Wednesday, June 19, 2024
AURN001 is the first allogeneic cell therapy to receive both FDA designations for the treatment of corneal edema secondary to corneal endothelial disease.
Wednesday, June 19, 2024
Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70% relative average improvement on the primary endpoint compared to patients who received placebo.
Tuesday, June 18, 2024
Learn about effective prevention and treatment options for myopia, including lifestyle changes and advanced management strategies.
Tuesday, June 18, 2024
AEYE Health recently announced FDA clearance for the AEYE Aurora, a handheld device from Optomed that can diagnose referable diabetic retinopathy from retinal images.
Tuesday, June 11, 2024
Improvements across multiple signs of efficacy endpoints were observed in the full population, and with a predictive and more pronounced effects in the TNFR1 genetic biomarker population
Tuesday, June 11, 2024
House of Delegates approves reforms to deliver greater transparency and accountability on the part of insurers.
Monday, June 10, 2024
Among the complaints reported were conjunctivitis, itchy eyes, swollen eyelids and respiratory failure
Monday, June 10, 2024
Water-free cyclosporine 0.1% ophthalmic solution shown to be safe and well tolerated during long-term use
Friday, June 7, 2024
A study found that low-dose daily aspirin does not prevent the development or progression of AMD in older adults.
Friday, June 7, 2024
Collaboration aims to improve imaging modalities for eye tissues in both clinical and research settings
Wednesday, June 5, 2024
Blink NutriTears targets key root causes of dry eyes and promotes healthy tear production
Wednesday, June 5, 2024
The RS-1 Glauvas delivers greater efficiency, patient comfort and accruate, early imaging.
By Rene Luthe
Wednesday, June 5, 2024
POCKET III features a measurement range from 150 μm to 1200 μm.
Tuesday, June 4, 2024
Dry eye therapy temporarily blocks tear drainage by the occlusion of the canalicular system
Tuesday, June 4, 2024
Therapy treats patients with mild to moderate DED and other ocular surface conditions
Thursday, May 30, 2024
The device is now supported with an OCT reference database and advanced cybersecurity features.
Wednesday, May 29, 2024
Premium IOL researchers can use the tool to evaluate patient-reported symptoms.
By Rene Luthe
Wednesday, May 29, 2024
Acquisition expands Merck’s presence in ophthalmology
Wednesday, May 29, 2024
Inaugural grants aim to help advance research into retinal diseases caused by mutations in the PRPH2 gene.
Tuesday, May 28, 2024
Opthea Limited program will assess safety and superior efficacy of sozinibercept for the treatment of patients with wet AMD.
Thursday, May 23, 2024
Adult glaucoma patients get a new option as New World Medical's KDB Glide receives indication expansion.
By Rene Luthe
Tuesday, May 21, 2024
Free resources include webpage, fact sheets, expert interview video and social media graphics.
Tuesday, May 21, 2024
Yesafili is a VEGF inhibitor that targets several ophthalmology conditions
Friday, May 17, 2024
Imaging module features a second 4K camera aimed at increasing detail
Thursday, May 16, 2024
The FDA gives AI-powered home retinal imaging service its marketing authorization for novel medical devices.
By Rene Luthe
Thursday, May 16, 2024
Handheld tonometer provides IOP measurements and eliminates the need for topical anesthetic.
Tuesday, May 14, 2024
Annexon's ANX007 provided broad-based protection against vision loss and protected key retinal structures.
Tuesday, May 14, 2024
'Early Detection of Vision Impairments for Children Act' is a bipartisan proposal.
Tuesday, May 14, 2024
MiDROPS shown safe and effective for moderate to severe DED in Phase 2 trial.
Friday, May 10, 2024
Alliance aims to advance ophthalmic diagnostics and personalized treatment approaches
Thursday, May 9, 2024
‘Healthcare from the Eye’ aims to improve health care access, cost and quality
Wednesday, May 8, 2024
Johnson & Johnson debuts EYE-RD Global Registry; RetiSpec, Topcon to develop AI diagnostic tool; and more.
Wednesday, May 1, 2024
FDA approves LUMIFY preservative-free eyedrops; FDA clears fully autonomous AI for portable DR screening; and more.
Wednesday, April 24, 2024
Positive data for MGD treatment; new research could unlock immunotherapy for rare eye cancer; and more.
Wednesday, April 17, 2024
Regeneron issues response to DOJ filing related to Eylea; iHealthScreen awarded patent on AI glaucoma detection model; and more.
Wednesday, April 10, 2024
Positive Phase 3 data for presbyopia treatment; RxSight launches its newest Light Adjustable Lens, the LAL+; and more.
Monday, April 8, 2024
Experts discuss recent advances in glaucoma diagnostics.
By Jim Gallagher, senior managing editor
Monday, April 8, 2024
The VisuMax 800 femtosecond laser, recently approved by the FDA, demonstrates power and efficiency.
By Jim Gallagher, senior managing editor
Monday, April 8, 2024
OOSS celebrates a year of successes, welcomes new board leadership at Perspective 2024 luncheon.
By Jim Gallagher, senior managing editor
Monday, April 8, 2024
Anterior segment surgeons provide pearls for crisis management.
By Jim Gallagher, senior managing editor
Monday, April 8, 2024
ASCRS and ASOA leaders encourage clinics and surgery centers to reduce waste and embrace sustainable practices.
By Jim Gallagher, senior managing editor
Sunday, April 7, 2024
Experts discussed the various options to treat aging eyes.
By Jim Gallagher, senior managing editor
Sunday, April 7, 2024
Proponents of ophthalmic office-based surgery believe that it provides an ideal way to address the growing need for cataract surgery.
Sunday, April 7, 2024
Useful tips and techniques for anterior segment surgeons was the focus of ASCRS lecture.
By Jim Gallagher, senior managing editor
Sunday, April 7, 2024
Experts provide tips and strategies to help ophthalmic practices thrive despite declining reimbursement.
By Jim Gallagher, senior managing editor
Sunday, April 7, 2024
Although the initial response has been tepid, presbyopia-correcting drops can still be an excellent choice for certain patients.
By Jim Gallagher, senior managing editor
Saturday, April 6, 2024
Sessions focused on the latest innovations and techniques in corneal care, as experts presented case studies and surgical videos.
By Jim Gallagher, senior managing editor
Saturday, April 6, 2024
Experts discuss what's in store for physician reimbursement in 2024 at ASOA session.
By Jim Gallagher, senior managing editor
Saturday, April 6, 2024
New ASCRS president takes office, and deserving surgeons are honored for their accomplishments
By Jim Gallagher, senior managing editor
Saturday, April 6, 2024
Surgeons discuss the benefits of refractive lens exchange in Steinert Lecture
By Jim Gallagher, senior managing editor
Saturday, April 6, 2024
Experts use real-world case studies to discuss surgical techniques and clnical advances in glaucoma treatment.
By Jim Gallagher, senior managing editor
Wednesday, April 3, 2024
J&J debuts Tecnis Odyssey IOL; Viatris launches RYZUMVl for mydriasis; and more.
Wednesday, March 27, 2024
CMS assigns J-code for GA treatment; glaucoma Mont Blanc Phase 3 trial results; and more.
Wednesday, March 20, 2024
Congress passes partial fix to Medicare physician payment; NovaBay, Eyenovia to co-promote prescription ophthalmic products; and more.
Wednesday, March 13, 2024
Regeneron reports positive data for treatment of wet AMD, DME; drug-eluting contact lens study shows sustained IOP reduction; and more.
Wednesday, March 6, 2024
Glaukos’ iDose TR commercially available in the US; CorNeat EverPatch synthetic tissue launched in US; and more.
Wednesday, February 28, 2024
Four eye ointments voluntarily recalled; CoFi announces market-wide availability of financing solution with CareCredit; and more.
Wednesday, February 21, 2024
New AI products designed to improve efficiency; FDA grants Breakthrough Device Designation for spectacle lenses; and more.
Wednesday, February 14, 2024
Meridian receives FDA approval for the MR Q family of lasers; Study shows Vyzulta’s safety, effectiveness at reducing IOP; and more.
Wednesday, February 7, 2024
FDA warns of contaminated copycat eyedrops; Genentech reports positive long-term data for Vabysmo; and more.
Wednesday, January 31, 2024
AAO warns against eye color-changing surgeries; new company Eyconis formed to develop Ascendis Pharma ophthalmology assets; and more.
Wednesday, January 24, 2024
MIGS device market growth rate of more than 5% expected; Outlook receives FDA agreement for trial; and more.
Wednesday, January 17, 2024
FDA clears Zeiss femtosecond laser for nearsightedness; NIDEK introduces scanning laser ophthalmoscope; and more.
Wednesday, January 10, 2024
FDA approves Bausch + Lomb’s TENEO LASIK platform for myopia and myopic astigmatism; Alcon reports positive data for DED treatment; and more.
Wednesday, January 3, 2024
Five Medicare Administrative Contractors retired their local coverage determinations for MIGS that were scheduled to take effect on Jan. 29, 2024; Harrow partners with three health-care technology platforms to expand US availability of VEVYE; and more.
